siRNA has also shown therapeutic potential in PD, where inhibition of α-synuclein (SNCA) expression decreases protein aggregation and preserves dopaminergic neurons, thereby alleviating motor deficits [24]. The gene discussed is SNCA; the disease is Parkinson disease.